Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

Injections 3Cytarabine 3pegylated granulocyte colony-stimulating factor 2Decitabine 2Daunorubicin 2Cladribine 2Biopsy 2Azacitidine 2venetoclax 1ruxolitinib 1fludarabine phosphate 1fedratinib 1enasidenib 1Whole-Body Irradiation 1Tacrolimus 1Spinal Puncture 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mitoxantrone 1Liposomes 1Gemtuzumab 1Cyclophosphamide 1CPX-351 1Bone Marrow Transplantation 12'-chloro-2'-deoxyadenosine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Monocytic, Acute × enasidenib × 90 days × Clear all
NCT05282459 2026-04-17

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Stanford University

Phase 1/2 Completed
17 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡